| Sep 3 |
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
|
| Sep 2 |
Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?
|
| Aug 28 |
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
| Aug 22 |
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
|
| Aug 22 |
Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
|
| Aug 21 |
Lexicon to face FDA AdCom over diabetes therapy review
|
| Aug 21 |
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
|
| Aug 14 |
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
|
| Aug 13 |
Lexicon to cut 50% of workforce to focus on sotagliflozin
|
| Aug 13 |
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
|
